ADVERTISEMENT

Home|Journals|Articles by Year|Audio Abstracts
 

Case Report

EJMCR. 2019; 3(3): 112-115


Rivaroxaban-induced skin necrosis: a case report

Mosaad Abelhameed Soliman,Khalid AbdelAziz Mowafy,Nashaat Abdrabo Elsaadany,Rana Ibraheem Soliman,Sameh Ibraheem Awad,Reem Ibraheem Soliman.



Abstract
Download PDF Cited by 3 ArticlesPost

Background: Even though rivaroxaban has been mainly associated with hemorrhage-related adverse effects, rivaroxaban-induced skin necrosis has received less attention or went unrecognized. Little has been documented about hypersensitivity reactions caused by the treatment with rivaroxaban. Case Presentation: This paper reports a skin necrosis with an apparent similarity to skin adverse events caused by the different anticoagulants. It happened in a 30-year-old female patient during rivaroxaban treatment. The correlation of the skin lesions to the used drug was made by the act of repeated discontinuation and reuse of rivaroxaban and the noticed remission and exacerbation of skin necrosis. Conclusion: This case highlights the vigilance required by healthcare in recognizing potential adverse effects of newly marketed drugs and in making medication changes whenever necessary.

Key words: Rivaroxaban, adverse effects, anaphylaxis, hypersensitivity, skin necrosis.







Bibliomed Article Statistics

29
29
25
29
44
57
32
29
21
37
22
24
R
E
A
D
S

9

11

21

32

30

73

61

60

45

54

36

32
D
O
W
N
L
O
A
D
S
010203040506070809101112
2025

Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Author Tools
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.